This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock XTLB vs. KZR, RVPH, LVTX, MRNS, FGEN, AKTX, CVKD, ALLK, ATHE, and OSTXShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Kezar Life Sciences (KZR), Reviva Pharmaceuticals (RVPH), LAVA Therapeutics (LVTX), Marinus Pharmaceuticals (MRNS), FibroGen (FGEN), Akari Therapeutics (AKTX), Cadrenal Therapeutics (CVKD), Allakos (ALLK), Alterity Therapeutics (ATHE), and OS Therapies (OSTX). These companies are all part of the "pharmaceutical preparations" industry. XTL Biopharmaceuticals vs. Kezar Life Sciences Reviva Pharmaceuticals LAVA Therapeutics Marinus Pharmaceuticals FibroGen Akari Therapeutics Cadrenal Therapeutics Allakos Alterity Therapeutics OS Therapies Kezar Life Sciences (NASDAQ:KZR) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership, community ranking and analyst recommendations. Does the media prefer KZR or XTLB? In the previous week, Kezar Life Sciences' average media sentiment score of 0.00 equaled XTL Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Kezar Life Sciences Neutral XTL Biopharmaceuticals Neutral Do analysts prefer KZR or XTLB? Kezar Life Sciences presently has a consensus price target of $39.50, indicating a potential upside of 849.52%. Given Kezar Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kezar Life Sciences is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in KZR or XTLB? Kezar Life Sciences received 58 more outperform votes than XTL Biopharmaceuticals when rated by MarketBeat users. However, 71.82% of users gave XTL Biopharmaceuticals an outperform vote while only 57.08% of users gave Kezar Life Sciences an outperform vote. CompanyUnderperformOutperformKezar Life SciencesOutperform Votes13757.08% Underperform Votes10342.92% XTL BiopharmaceuticalsOutperform Votes7971.82% Underperform Votes3128.18% Which has preferable earnings and valuation, KZR or XTLB? XTL Biopharmaceuticals has lower revenue, but higher earnings than Kezar Life Sciences. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKezar Life Sciences$7M4.34-$101.87M-$11.55-0.36XTL BiopharmaceuticalsN/AN/A-$1.78MN/AN/A Is KZR or XTLB more profitable? XTL Biopharmaceuticals' return on equity of 0.00% beat Kezar Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Kezar Life SciencesN/A -54.95% -46.11% XTL Biopharmaceuticals N/A N/A N/A Which has more volatility & risk, KZR or XTLB? Kezar Life Sciences has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Do insiders & institutionals have more ownership in KZR or XTLB? 67.9% of Kezar Life Sciences shares are owned by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. 9.3% of Kezar Life Sciences shares are owned by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. SummaryKezar Life Sciences and XTL Biopharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.16M$6.46B$5.31B$7.35BDividend YieldN/A3.20%5.45%4.29%P/E RatioN/A6.9521.9417.81Price / SalesN/A231.03380.9597.68Price / CashN/A65.6738.2634.64Price / Book2.765.936.453.98Net Income-$1.78M$143.22M$3.22B$247.81M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL BiopharmaceuticalsN/A$1.13flatN/AN/A$6.16MN/A0.00N/AKZRKezar Life Sciences3.741 of 5 stars$4.32+9.4%$39.50+814.4%-47.3%$31.56M$7M-0.3360RVPHReviva Pharmaceuticals2.2794 of 5 stars$0.78+15.0%$10.00+1,188.5%-74.1%$31.54MN/A-0.705Upcoming EarningsNews CoverageLVTXLAVA Therapeutics2.3868 of 5 stars$1.16+6.4%$3.17+173.0%-51.7%$30.51M$11.98M-1.1360Short Interest ↓Positive NewsGap UpMRNSMarinus Pharmaceuticals2.1392 of 5 stars$0.55-0.2%$4.79+771.6%-60.2%$30.32M$30.99M-0.22110Analyst ForecastNews CoverageFGENFibroGen4.1332 of 5 stars$0.30+8.2%$10.00+3,234.4%-75.1%$30.27M$29.62M-0.24570Analyst ForecastGap DownAKTXAkari TherapeuticsN/A$1.11+4.0%N/A+3.2%$29.60MN/A0.009Analyst ForecastCVKDCadrenal Therapeutics1.9798 of 5 stars$15.45+3.0%$32.00+107.1%N/A$29.05MN/A-2.314News CoveragePositive NewsGap UpALLKAllakos4.1302 of 5 stars$0.32+0.0%$2.00+524.0%-69.5%$28.91MN/A-0.16190High Trading VolumeATHEAlterity Therapeutics2.5724 of 5 stars$3.21+2.6%$12.00+273.8%+71.6%$28.46MN/A0.0010Short Interest ↓Gap DownOSTXOS Therapies2.1502 of 5 stars$1.31+4.8%$18.00+1,274.0%N/A$28.38MN/A0.00N/A Related Companies and Tools Related Companies Kezar Life Sciences Competitors Reviva Pharmaceuticals Competitors LAVA Therapeutics Competitors Marinus Pharmaceuticals Competitors FibroGen Competitors Akari Therapeutics Competitors Cadrenal Therapeutics Competitors Allakos Competitors Alterity Therapeutics Competitors OS Therapies Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XTLB Stock Free XTLB Stock Alerts